0.6051
price down icon8.29%   -0.0547
after-market Handel nachbörslich: .61 0.0049 +0.81%
loading
Schlusskurs vom Vortag:
$0.6598
Offen:
$0.66
24-Stunden-Volumen:
271.05K
Relative Volume:
0.22
Marktkapitalisierung:
$3.30M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-48.85M
KGV:
-0.2619
EPS:
-2.31
Netto-Cashflow:
$-46.25M
1W Leistung:
+12.24%
1M Leistung:
-24.36%
6M Leistung:
-95.86%
1J Leistung:
-99.49%
1-Tages-Spanne:
Value
$0.59
$0.66
1-Wochen-Bereich:
Value
$0.4843
$0.69
52-Wochen-Spanne:
Value
$0.4843
$121.40

Vincerx Pharma Inc Stock (VINC) Company Profile

Name
Firmenname
Vincerx Pharma Inc
Name
Telefon
650-800-6676
Name
Adresse
260 SHERIDAN AVENUE, PALO ALTO
Name
Mitarbeiter
42
Name
Twitter
Name
Nächster Verdiensttermin
2025-04-01
Name
Neueste SEC-Einreichungen
Name
VINC's Discussions on Twitter

Vergleichen Sie VINC mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
VINC
Vincerx Pharma Inc
0.6051 3.30M 0 -48.85M -46.25M -2.31
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.62 125.40B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
573.45 65.79B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
555.11 35.18B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
235.74 32.67B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
238.51 26.46B 3.81B -644.79M -669.77M -6.24

Vincerx Pharma Inc Stock (VINC) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2022-01-14 Eingeleitet H.C. Wainwright Buy
2021-12-23 Eingeleitet Cantor Fitzgerald Overweight
2021-11-01 Eingeleitet SVB Leerink Outperform
2021-09-13 Eingeleitet Laidlaw Buy
2021-08-25 Eingeleitet B. Riley Securities Buy

Vincerx Pharma Inc Aktie (VINC) Neueste Nachrichten

pulisher
Mar 31, 2025

VINC Stock Plummets to 52-Week Low of $0.48 Amid Steep Decline - Investing.com

Mar 31, 2025
pulisher
Mar 31, 2025

VINC Stock Plummets to 52-Week Low of $0.48 Amid Steep Decline By Investing.com - Investing.com South Africa

Mar 31, 2025
pulisher
Mar 28, 2025

Vincerx Pharma (VINC) Projected to Post Quarterly Earnings on Friday - Defense World

Mar 28, 2025
pulisher
Mar 27, 2025

Vincerx Pharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 27, 2025
pulisher
Mar 25, 2025

Vincerx Pharma Inc expected to post a loss of $3.40 a shareEarnings Preview - TradingView

Mar 25, 2025
pulisher
Mar 19, 2025

Such Is The Power Of Vincerx Pharma Inc (NASDAQ: VINC) - Stocks Register

Mar 19, 2025
pulisher
Mar 19, 2025

Vincerx Pharma plans reverse merger with QumulusAI By Investing.com - Investing.com Australia

Mar 19, 2025
pulisher
Mar 18, 2025

Vincerx Pharma Announces Non-Binding Letter of Intent for Business Combination with QumulusAI - GlobeNewswire

Mar 18, 2025
pulisher
Mar 18, 2025

VINC stock touches 52-week low at $0.73 amid sharp annual decline - Investing.com UK

Mar 18, 2025
pulisher
Mar 18, 2025

Vincerx Pharma Plans Reverse Merger With AI Infrastructure Firm QumulusAI -March 18, 2025 at 09:40 am EDT - Marketscreener.com

Mar 18, 2025
pulisher
Mar 18, 2025

Vincerx Pharma plans reverse merger with QumulusAI - Investing.com India

Mar 18, 2025
pulisher
Mar 18, 2025

Vincerx Pharma Announces Non-Binding Letter of Intent for Business Combination with QumulusAI - Benzinga

Mar 18, 2025
pulisher
Mar 18, 2025

Vincerx Pharma's $300M AI Transformation: QumulusAI Merger Creates New Computing Powerhouse - StockTitan

Mar 18, 2025
pulisher
Mar 03, 2025

Vincerx Pharma Plunges After Scrapping Reverse Merger With Oqory And Vivaso - Nasdaq

Mar 03, 2025
pulisher
Mar 02, 2025

Vincerx Pharma terminates reverse merger term sheet and evaluates strategic alternatives - MSN

Mar 02, 2025
pulisher
Feb 28, 2025

Vincerx Pharma Terminates Reverse Merger Deal With Oqory - MarketWatch

Feb 28, 2025
pulisher
Feb 28, 2025

Vincerx Pharma Explores Strategic Alternatives Post Merger Termination - TipRanks

Feb 28, 2025
pulisher
Feb 28, 2025

Vincerx Pharma Announces Termination Of Reverse Merger Term Sheet -February 28, 2025 at 04:12 pm EST - Marketscreener.com

Feb 28, 2025
pulisher
Feb 28, 2025

Vincerx Pharma announces termination of reverse merger term sheet - TipRanks

Feb 28, 2025
pulisher
Feb 28, 2025

Vincerx Pharma Announces Termination of Reverse Merger Term Sheet and Evaluation of Strategic Alternatives - The Manila Times

Feb 28, 2025
pulisher
Feb 28, 2025

Vincerx Pharma, Inc. Terminates Reverse Merger Agreement and Will Explore Strategic Alternatives - Nasdaq

Feb 28, 2025
pulisher
Feb 28, 2025

Is Vincerx Pharma Running Out of Options? Merger Deal Collapses as Cash Dwindles - StockTitan

Feb 28, 2025
pulisher
Feb 28, 2025

Vincerx Pharma, Inc. (NASDAQ:VINC) Short Interest Update - Defense World

Feb 28, 2025
pulisher
Feb 24, 2025

VINC stock touches 52-week low at $1.17 amid market challenges - Investing.com Australia

Feb 24, 2025
pulisher
Feb 24, 2025

VINC stock touches 52-week low at $1.17 amid market challenges By Investing.com - Investing.com South Africa

Feb 24, 2025
pulisher
Feb 18, 2025

Vincerx Pharma Regains Compliance With Nasdaq Listing Rule 5550(A)(2) -February 18, 2025 at 05:27 pm EST - Marketscreener.com

Feb 18, 2025
pulisher
Feb 16, 2025

Vincerx Pharma announces reverse stock split; shares drop - MSN

Feb 16, 2025
pulisher
Feb 13, 2025

VINC stock touches 52-week low at $1.3 amid market challenges - Investing.com Australia

Feb 13, 2025
pulisher
Feb 02, 2025

Vincerx Pharma, Inc. (NASDAQ:VINC) Sees Large Increase in Short Interest - MarketBeat

Feb 02, 2025
pulisher
Jan 31, 2025

Short Interest in Vincerx Pharma, Inc. (NASDAQ:VINC) Rises By 1,022.5% - MarketBeat

Jan 31, 2025
pulisher
Jan 29, 2025

VINC stock touches 52-week low at $1.62 amid market challenges - Investing.com Canada

Jan 29, 2025
pulisher
Jan 29, 2025

Vincerx Pharma, Oqory highlight Phase 1a/1b data for OQY-3258 - TipRanks

Jan 29, 2025
pulisher
Jan 29, 2025

Vincerx Pharma and Oqory reveal merger and cancer drug data - Investing.com

Jan 29, 2025
pulisher
Jan 29, 2025

Vincerx Pharma, Inc. and Oqory, Inc. Highlight Promising Data for Oqory’s TROP2 Antibody Drug Conjugate, OQY-3258 - GlobeNewswire

Jan 29, 2025
pulisher
Jan 29, 2025

Vincerx Pharma and Oqory reveal merger and cancer drug data By Investing.com - Investing.com UK

Jan 29, 2025
pulisher
Jan 29, 2025

Revolutionary Cancer Treatment Achieves Unprecedented 80% Success Rate in Clinical Trial - StockTitan

Jan 29, 2025
pulisher
Jan 28, 2025

Stock market news: Vincerx Pharma plunged by 95.86% while MiNK Therapeutics was down by 94.26% during mid day trading - Business Upturn

Jan 28, 2025
pulisher
Jan 28, 2025

Vincerx Pharma enters at-the-market equity offering deal - MSN

Jan 28, 2025
pulisher
Jan 28, 2025

Stock market today: Vincerx Pharma declined by 95.75% whereas Revelation Biosciences - Business Upturn

Jan 28, 2025
pulisher
Jan 27, 2025

Vincerx Pharma (NASDAQ:VINC) Stock Quotes, Forecast and News Summary - Benzinga

Jan 27, 2025
pulisher
Jan 27, 2025

Why Logility Supply Chain Solutions Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarket - Benzinga

Jan 27, 2025
pulisher
Jan 26, 2025

Vincerx Pharma files for $100M mixed securities shelf - MSN

Jan 26, 2025
pulisher
Jan 26, 2025

Vincerx Pharma (NASDAQ:VINC) Implements 1-for-20 Reverse Stock Split - Defense World

Jan 26, 2025
pulisher
Jan 24, 2025

Palo Alto's Vincerx Pharma plans reverse stock split amid merger plans - The Business Journals

Jan 24, 2025
pulisher
Jan 24, 2025

Vincerx Pharma (VINC) Stock Price, News & Analysis - MarketBeat

Jan 24, 2025
pulisher
Jan 23, 2025

Vincerx Pharma Inc. Announces Merger with Oqory - TipRanks

Jan 23, 2025
pulisher
Jan 23, 2025

Vincerx Pharma, Inc. Announces Reverse Stock Split - The Manila Times

Jan 23, 2025

Finanzdaten der Vincerx Pharma Inc-Aktie (VINC)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$60.26
price down icon 10.70%
$69.18
price down icon 5.66%
$17.36
price down icon 8.20%
$31.11
price down icon 2.14%
$88.05
price down icon 4.30%
biotechnology ONC
$238.51
price down icon 9.76%
Kapitalisierung:     |  Volumen (24h):